On the basis of cfDNA, through EGFR T790 M mutation testing using the cobas® EGFR Mutation Test v2, non-small cell lung cancer (NSCLC) patients can be stratified for treatment with third-generation tyrosine kinase inhibitors without re-biopsy [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.